Stockscreener 앱 받기
3.07
2.54%
-0.08
시장 영업 전:
3.05
-0.02
-0.65%
Tuhura Biosciences Inc 주식(HURA)의 최신 뉴스
Rodman & Renshaw initiates TuHURA Biosciences stock with buy rating By Investing.com - Investing.com Australia
Rodman & Renshaw Initiates TuHURA Biosciences(HURA.US) With Buy Rating, Announces Target Price $7 - Moomoo
TuHURA Biosciences, Inc. (NASDAQ:HURA) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
TuHURA Biosciences (NASDAQ:HURA) Raised to Hold at Wall Street Zen - MarketBeat
Downgrade Watch: What is the target price for TuHURA Biosciences Inc stockWeekly Market Summary & AI Forecasted Stock Moves - baoquankhu1.vn
HURA.O PE Ratio & Valuation, Is HURA.O Overvalued - Intellectia AI
Aug Rallies: Does TuHURA Biosciences Inc. align with a passive investing strategyTrade Volume Report & Free Reliable Trade Execution Plans - baoquankhu1.vn
Hedge Fund Moves: Is TuHURA Biosciences Inc a strong candidate for buy and hold - baoquankhu1.vn
HURA: 2025 Financial Results - Yahoo Finance
TuHURA Biosciences Acquires Kineta in $16.6M Merger and Closes $12.6M Private Placement – Key Details and Financial Impact - Minichart
TuHURA Biosciences approves executive bonuses and salary increases By Investing.com - Investing.com India
TuHURA Biosciences Approves 2025 Executive Compensation Adjustments - TipRanks
TuHURA Biosciences approves executive bonuses and salary increases - Investing.com
Tuhura Biosciences Inc Enters At The Market Offering Agreement With H.C. Wainwright & Co. - TradingView — Track All Markets
TuHURA (NASDAQ: HURA) $50M ATM equity facility via H.C. Wainwright - Stock Titan
TuHURA awards bonuses to James Bianco and Dan Dearborn, adjusts salaries - TradingView
Kineta deal and $11.5M raise shape TuHURA Biosciences (NASDAQ: HURA) 2025 results - Stock Titan
TuHURA Appoints New SVP of Clinical Operations - Intellectia AI
TuHURA Biosciences Appoints Amanda Garofalo, MSHS, as Senior Vice President of Clinical Operations - Sahm
TuHURA Biosciences names Amanda Garofalo as clinical operations SVP By Investing.com - Investing.com Australia
TuHURA Biosciences names Amanda Garofalo as clinical operations SVP - Investing.com
TuHURA Biosciences (NASDAQ:HURA) Rating Lowered to Sell at Wall Street Zen - MarketBeat
HURA SEC FilingsTuHURA Biosciences 10-K, 10-Q, 8-K Forms - Stock Titan
Earnings Risk: What dividend growth rate does TuHURA Biosciences Inc offer2026 Closing Moves & Detailed Earnings Play Strategies - baoquankhu1.vn
EPS Watch: Does TuHURA Biosciences Inc stock reflect fundamentals2026 Technical Patterns & Fast Entry Momentum Trade Alerts - baoquankhu1.vn
TuHURA Biosciences, Inc. (NASDAQ:HURA): Is Breakeven Near? - Sahm
TuHURA Biosciences, Inc. (HURA) stock price, news, quote and history - Yahoo Finance UK
TuHURA Biosciences, Inc.'s (NASDAQ:HURA) Shift From Loss To Profit - Yahoo Finance
TuHURA Biosciences Reports 2025 Financial Results, Advances Phase 3 Cancer Trials and Expands Pipeline with VISTA Antibody Acquisition - Minichart
Tuhura Biosciences reports fourth quarter and full year 2025 financial results and provides a corporate update - marketscreener.com
Tuhura Biosciences Reports Fourth Quarter And Full Year 2025 Financial Results And Provides A Corporate Update - TradingView
TuHURA (Nasdaq: HURA) ramps R&D as IFx-2.0 enters Phase 3 - Stock Titan
TuHURA Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update - PR Newswire
TuHURA Biosciences (NASDAQ:HURA) Posts Earnings Results, Misses Expectations By $0.01 EPS - MarketBeat
TuHURA Biosciences (NASDAQ: HURA) maps Phase 3 trial and AML plans - Stock Titan
TuHURA R&D Jumps 75% in Q2 - AOL.com
Volatility Watch: Is TuHURA Biosciences Inc exposed to political riskDollar Strength & Free Daily Entry Point Trade Alerts - baoquankhu1.vn
TuHURA Biosciences, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
TuHURA Biosciences (NASDAQ:HURA) Upgraded by Wall Street Zen to Hold Rating - MarketBeat
TuHURA Biosciences Inc expected to post a loss of 13 cents a shareEarnings Preview - TradingView
Layoff Watch: Does TuHURA Biosciences Inc. align with a passive investing strategyEarnings Trend Report & Low Risk High Win Rate Picks - baoquankhu1.vn
TuHURA Biosciences, Inc. Common Stock (HURA) Stock Price Today & Analysis - Gotrade
TuHURA Biosciences appoints Craig Tendler as chief medical officer By Investing.com - Investing.com Australia
TuHURA Biosciences, Inc.Common Stock (NQ: HURA - The Chronicle-Journal
TuHURA Biosciences appoints Craig Tendler as chief medical officer - Investing.com
Craig Tendler, M.D., JNJ's Former Global Head of Oncology Clinical Development, to Lead TuHURA Bioscience's VISTA Program in AML and other Blood Related Cancers - ChartMill
TuHURA Biosciences (NASDAQ:HURA) Rating Lowered to "Sell" at Wall Street Zen - MarketBeat
Growth Report: How is TuHURA Biosciences Inc managing supply chain issuesWeekly Earnings Recap & Consistent Growth Equity Picks - baoquankhu1.vn
HURA Earnings History & Surprises | EPS & Revenue Results | TUHURA BIOSCIENCES INC (NASDAQ:HURA) - ChartMill
TuHURA Biosciences (HURA) Expected to Release Quarterly Earnings on Thursday - MarketBeat
Bull Bear: Is TuHURA Biosciences Inc a strong candidate for buy and hold2026 Earnings Surprises & Free AI Powered Buy and Sell Recommendations - baoquankhu1.vn
2.69%
0.25%
자본화:
|
볼륨(24시간):